𝔖 Bobbio Scriptorium
✦   LIBER   ✦

PRM109 Content Validity of a Treatment Satisfaction Questionnaire in Non-Hodgkin's Lymphoma

✍ Scribed by Campbell, A.; Wiesner, C.; Garcia, E.B.; Tatlock, S.; Humphrey, L.

Book ID
121927700
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
59 KB
Volume
15
Category
Article
ISSN
1098-3015

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

CEOP treatment results and validity of t
CEOP treatment results and validity of the International Prognostic Index in Chinese patients with aggressive non-Hodgkin's lymphoma
✍ C. S. Chim; Y. L. Kwong; A. K. W. Lie; C. K. Lee; R. Liang πŸ“‚ Article πŸ“… 1998 πŸ› John Wiley and Sons 🌐 English βš– 125 KB πŸ‘ 2 views

From 1991 to 1997, we have treated 78 newly diagnosed patients with aggressive non-Hodgkin's lymphoma with a modified CHOP regimen in which epirubicin (60 mg/m 2 ) was used in place of doxorubicin (50 mg/m 2 ), i.e. CEOP (cyclophosphamide, epirubicin, vincristine and prednisolone). The median age wa

Treatment of low-grade non-Hodgkin's lym
Treatment of low-grade non-Hodgkin's lymphomas: Assessment of doxorubicin in a controlled trial
✍ Dr. E. Lepage; C. Sebban; C. Gisselbrecht; B. Coiffier; J. L. Harousseau; P. A. πŸ“‚ Article πŸ“… 1990 πŸ› John Wiley and Sons 🌐 English βš– 501 KB

From 1981 to 1984 a randomized clinical trial was conducted to evaluate the role of doxorubicin in low grade malignancy non-Hodgkin's lymphoma (NHL). One hundred and thirteen patients were treated by an induction regimen including cyclophosphamide 400 mg/m2 day I and 8, vincristine 1.4 mg/m2 day 1 a